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Circulating adhesion molecules (CAMs), surface proteins expressed in the vascular endothelium, have emerged as risk factors for
cardiovasculardisease(CVD).CAMs are involvedin intercellular communicationthatare believed to playarole inatherosclerosis.
A Chinese medicine, the “Dantonic Pill” (DP) (also known as the “Cardiotonic Pill”), containing three Chinese herbal material
medica, Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum, has been used in China for the prevention
and managementofCVD. Previous laboratoryand animalstudies have suggested that this preparation reduces both atherogenesis
and adhesion molecule expression. A parallel double blind randomized placebo-controlled study was conducted to assess the
eﬀects ofthe DP onthree species of CAM (intercellular cell adhesionmolecule-1 (ICAM-1), vascularcell adhesion molecule-1 and
endothelial cell selectin (E-selectin)) in participants with mild-moderate hypercholesterolemia. Secondary endpoints included
biochemical and hematological variables and clinical eﬀects. Forty participants were randomized to either treatment or control
for 12 weeks. Treatment with DP was associated with a statistically signiﬁcant decrease in ICAM-1 (9% decrease, P = .03) and
E-Selectin (15% decrease, P = .004). There was no signiﬁcant change in renal function tests, liver function tests, glucose, lipids or
C-reactive proteinlevelsandclinicaladverseeﬀects didnotdiﬀerbetween theactiveandthecontrolgroups.There werenorelevant
changes in participants receiving placebo. These results suggest that this herbal medicine may contribute to the development of a
novel approach to cardiovascular risk reduction.
1.Introduction
Circulating adhesion molecules (CAMs) are proteins ex-
pressed by the vascular endotheliuminvolved in intercellular
communication that are believed to play a role in the
initiation of the atherosclerotic process. There are several
families of CAMs, including integrins, cadherins, selectins
and immunoglobulin superfamily members [1]. The most
important adhesion molecules involved in atherosclerosis
appear to be intercellular cell adhesion molecule-1 (ICAM-
1), endothelial cell selectin (E-selectin) and vascular cell
adhesion molecule-1 (VCAM-1). Raised levels of ICAM-
1h a v eb e e nf o u n dt ob ep r e d i c t i v eo fi n c r e a s e dr i s ko f
cardiovascular events [2, 3], including in healthy individuals
[4]. Levels of P-selectin and E-selectin have been found
to predict cardiovascular disease (CVD) risk in healthy
women [5], and in patients with stable coronary artery
disease plasma levels of E-selectin appear to reﬂect the
severity of systemic atherosclerosis [6]. VCAM-1 may be a
more speciﬁc marker for advanced atherosclerosis, since it is
usually expressed in atherosclerotic plaques [7]a n dh i g h e r
levels are associated with increased risk of coronary events2 Evidence-Based Complementary and Alternative Medicine
in persons with existing CVD [2]. There is some evidence
that measures, which reduce circulating levels of adhesion
molecules also reduce cardiovascular risk [8, 9].
TheuseofherbsandherbaltherapiesinWesternsocieties
is extensive and increasing, especially for the prevention
of illness and the management of chronic disease. Radix
Salviae Miltiorrhizae (Chinese herb Dan Shen) and Radix
Notoginseng (San Qi) are medicinal herbs (material medica)
commonly used in traditional Chinese medicine practice
to prevent or treat conditions relating to the heart and
blood vessels. A mixture of these two herbs, together with
a third materia medica—Borneolum Syntheticum (Bing
Pian)—is produced by the Tianjin Tasly Pharmaceutical
Co., Ltd, Tianjin, China, under the name of the “Dantonic
Pill” (DP) (also known as the “Cardiotonic Pill”), under
conditions of “Good Manufacturing Practice” (GMP) and
“Good Laboratory Practice” (GLP) veriﬁed by Chinese,
Australian and US Government agencies. This product has
been sold in China for ∼8 years, predominantly for the
prevention and treatment of CVD [10]. Laboratory studies
have shown that this product displays a range of activities
in the cardiovascular system, including reduction in venous
thrombosis [11] and blood viscosity [12].
We have previously shown that in cultured human
vascular endothelial cells DP signiﬁcantly attenuates tumor
necrosis factor α-induced expression of adhesion molecules
ICAM-1 and VCAM-1 in a dose-dependent manner and
inhibits platelet-derived growth factor BB-induced DNA
synthesis and cell proliferation in cultured human vascular
smooth muscle cells [13, 14]. In addition, we have found
that in a mouse model of atherosclerosis—apolipoprotein E
deﬁcientmicefedanatherogenicdiet—administration ofDP
prevents increases in VCAM-1 expression and inhibits the
development of fatty streaks and atherosclerotic plaques in
the thoracic aorta without altering levels of circulating lipids
[15].
The study reported here was designed to examine the
eﬀects of DP on expression of adhesion molecules in human
subjects with mild to moderate hypercholesterolemia and to
obtain data about the tolerability and safety of this product
in a Western population.
2.Methods
2.1. Study Design and Participants. The study employed
a parallel double-blinded, randomized, placebo controlled
design. Forty subjects with mild to moderately elevated
cholesterol were randomly allocated to receive either DP or
matching placebofor12weeks. Thestudy waspartofalarger
investigation of the eﬀects of Chinese medicinal herbs on
cardiovascular risk, other aspects of which will be reported
elsewhere. The study was carried out in accordance with
the Declaration of Helsinki (2000) of the World Medical
Association.
Participants were healthy individuals aged 18 years and
over with a total plasma cholesterol of 5.0mmol/l or above,
triglyceride level of >2mmol/l or HDL level of <1.0mmol/l.
Exclusion criteria included plasma triglyceride levels over
10mmol/l,establishedheartdisease,otherseriousmedicalor
psychological conditions, pregnancy, current use of vasoac-
tive medications, warfarin and postmenopausal hormone
therapy. Participants taking omega-3 ﬁsh oil supplements
were asked to cease these at least 3 weeks prior to entering
the study. Participants were recruited via newspaper adver-
tisements and posters displayed at the Alfred Hospital in
Melbourne, Australia. Ethics approval was obtainedfrom the
Alfred Hospital Ethics Committee and Monash University
and all participants gave full consent.
Following baseline assessment (Visit 1) participants were
randomized to receive either DP or placebo in capsule form,
three capsules three times per day for 12 weeks, after which
theassessment wasrepeated(Visit2).Participants wereasked
to maintain their current diets and exercise regimes during
the study period. They were contacted by telephone every
3 weeks to ascertain side eﬀects and encourage compliance,
which was assessed by examination of unused returned
packets. They were also asked to complete a 4-day diet diary
and exercise questionnaire during the ﬁrst and last weeks of
the study.
2.2. Outcome Variables. The primary outcome variables
were circulating levels of ICAM-1, VCAM-1 and E-selectin.
Secondary outcomes included serum urea, electrolytes, crea-
tinine, glucose, liver function, lipids, full blood examination
and high-sensitivity C-reactive protein.
2.3. Chinese Herbal Mixture. T h eD Pi sa nh e r b a lp r o d u c t
produced by Tianjin Tasly Pharmaceutical Corporation Ltd
in China consisting of a mixture of three Chinese materia
medica: Radix Salviae Miltiorrhizae, Radix Notoginseng
and Borneolum Syntheticum. Both the preparation and
the individual herbs have been approved by the Australian
Therapeutic Goods Administration for use in Australia and
are widely available.
Animal toxicity studies of the DP conducted in China
and reported by the Tianjin Tasly Pharmaceutical Company
demonstrated no toxic eﬀects in mice in studies up to 6
months duration. The lethal dosage (LD50) of DP extract
was assessed via single gastric canal on mice and was
calculated using the “Bliss Method” as recommended in the
Chinese Government’s New Drug (Chinese Medicine) Pre-
Clinical Research Guidelines [16]. The LD50 was found to be
25.807g/kg, equivalent to 3934 times the intended clinical
human oral dose of 6.56mg/kg.
2.4. Laboratory Techniques. Expression of ICAM-1, VCAM-
1 and E-selectin in circulating leukocytes was determined
by ﬂuorescence-activated cell sorting (FACS)analysis. Whole
blood cells were collected after separation of the plasma,
incubated in the lysis buﬀer (BD Pharm Lyse (Cat. No.
555899), BD Biosciences Pharmingen, San Diego, CA, USA)
for 10min at 37
◦C and washed in PBS to remove the
red blood cells, and the leukocytes were re-suspended in
0.5mL Hanks’ balanced salt solution (HBSS). Cells were
incubated with a speciﬁc ﬂuorescence-connected antibody
against ICAM-1, VCAM-1 or E-selectin (BD Biosciences,Evidence-Based Complementary and Alternative Medicine 3
Table 1: Baseline characteristics of experimental and control
groups.
Characteristic DP group
(n = 20)
Placebo group
(n = 20)
Male/female 8/12 7/13
Mean age (years) 53.3 ±10.75 1 .6 ±14.4
Body mass index
(kg/m2) 26.0 ±4.42 5 .2 ±3.6a
Smokers 0a 4
Mean no. standard
alcoholic drinks/week 3.6 ±2.6a 4.7 ±4.1
an = 19 (data not shown for one subject).
San Diego, CA, USA) for 1h, protected from light, then
washed in 0.5mL HBSS to remove residual antibody and
analyzed using the FACS scanning ﬂow cytometer and
CellQuest software (Becton Dickinson, Franklin Lakes, NJ,
USA).
Assays for other serum markers were conducted in the
Pathology Department of the Alfred Hospital using estab-
lished techniques. These included total serum cholesterol,
triglycerides,HDL-cholesterolandC-reactiveprotein(Roche
methodforﬁrst3monthsthenAbbottmethodforremainder
of study, cross-calibrated for consistency of values), LDL
cholesterol (Abbott, Illinois, USA), homocysteine (Abbott
AxSym), ﬁbrinogen (Von Claus method on Diagnostica
Astago STAR), Von Willebrand Factor (ELISA manual
method).
2.5. Statistical Analysis. T h es t u d yw a sd e s i g n e dt ob ea b l et o
identify a 10% change in total serum cholesterol and LDL-
cholesterol with a Type 1 error of 0.05 with a power of
0.8. Within-groups analyses were conducted on all deﬁned
outcome variables. Where data were normal, the paired
Student t-test was used. Where tests for normality of data
were violated the Wilcoxon Signed Ranks Test was used.
At w o - s i d e dP-value of .05 was considered as statistically
signiﬁcant.
3.Results
A total of 40 subjects, 20 in each medication group,
completed the study protocol. The characteristics of par-
ticipants in each group are set out in Table 1.T h e r ew a s
no signiﬁcant diﬀerence between the two groups in terms
of mean age of participants, alcohol use, physical activity,
dietary content or body mass index. Physical activity did not
change signiﬁcantly in either group over the study period, as
measuredbytheBaeckePhysicalActivityQuestionnaire[17].
3.1. CAM. Circulating levels of ICAM-1 and E-selectin
decreasedsigniﬁcantlyintheDPgroup(by9and15%,resp .).
In the Placebo group there were no signiﬁcant changes in
any of the CAMs tested. There was no signiﬁcant change in
VCAM-1 levels in either group (Table 2).
3.2. Adverse Eﬀects. There was no diﬀerence in reported
adverse eﬀects between the two groups. Five participants
in the Placebo group and three in the DP group reported
various symptoms, predominantly gastrointestinal in nature,
such as bloating, alteration of stools, mild nausea, belching
and gastric reﬂux. One participant in the Placebo group
discontinued the study 6 weeks after randomization due to
indigestion.
3.3. Biochemical and Hematological Analyses. There were
no clinically or statistically signiﬁcant changes in urea
and electrolytes, blood glucose, lipids, hemoglobin, platelet
count, white cell count or C-reactive protein in either group
(data not shown). There were minor changes in derived
hematological parameters and bilirubin within the reference
range for normal adults in both groups, which were not
diﬀerent between the two groups. The liver enzyme alanine
transferase declined signiﬁcantly within the reference range
in the DP group (P = .02) but did not change in the Placebo
group.
4.Discussion
This study has shown that 12 weeks administration of
the Chinese herbal mixture DP to men and women with
mild-to-moderate elevation in lipid levels is associated with
reducedexpressionoftheCAMsICAM-1andE-selectin.The
study has also shown that in this setting the preparation is
well tolerated and free from signiﬁcant biochemical adverse
eﬀects.
CAMs have emerged as a risk factor for CVD. They
are believed to play important roles in the initiation of
the atherosclerotic process by mediating various steps in
leukocyte recruitment. Upregulation of adhesion molecule
expression in the development of atherogenesis has been
observed in both animal models and humans [18, 19].
Leukocyte recruitment to atherosclerosis sites is mediated by
CAM expressed on the surface of endothelial cells, which
bind circulating leukocytes to the vascular endothelium in
theearlyphaseofatherosclerosis[6].CAMgeneexpressionis
upregulated in inﬂammatory states through cytokine release
by various cells including endothelial cells, smooth muscle
cells and leukocytes [1]. Hemodynamic shear stress is also
able to increase ICAM-1 expression in addition to cytokine
stimulation [20]. ICAM-1 and VCAM-1 mediate stronger
attachment of leukocytes to the endothelium whilst the
selectins (E-selectin, P-selectin) mediate transient leukocyte
rolling on the endothelial surface [7, 20].
Raised levelsofICAM-1havebeenfound to bepredictive
of increased risk of cardiovascular events [2–4]. In patients
with stable coronary artery disease plasma levels of E-
selectin is synthesized and exported on the endothelial cell
surface ininﬂammatory situations[21]andappearstoreﬂect
the severity of systemic atherosclerosis [6]. P-selectin levels
predict CVD risk in healthy women [5]. VCAM-1 may be
a speciﬁc marker for advanced atherosclerosis, since it is
usually expressed on atherosclerotic plaques [7]a n dV C A M -
1 levelscorrelated with extent of atherosclerosis [22]. In view4 Evidence-Based Complementary and Alternative Medicine
Table 2: Within-groups analysis: CAMs (ICAM 1, VCAM and E-selectin).
Visit 1 Visit 2 Visit 1 Visit 2 Visit 1 Visit 2
ICAM-1 ICAM-1 VCAM-1 VCAM-1 E-SEL E-SEL
DP Mean 37.1 ±26.13 3 .8 ± 25.81 4 .2 ±10.11 4 .0 ±9.93 3 .0 ±25.32 8 .0 ±25.7
P (two-tailed t-test) 0.03 0.79 0.004a
N = 19
Placebo Mean 30.1 ±20.62 7 .4 ± 21.21 2 .0 ±8.11 1 .5 ±6.82 7 .9 ±16.22 4 .8 ±19.1
P (two-tailed t-test) 0.36a 0.97a 0.37a
N = 20
E-SEL = E-selectin; aWilcoxon Signed Ranks Test; Visit 1—baseline measurements;Visit 2—measurementstaken after 12 weeks of study medication.
ofthese facts, ithasbeenargued thatadhesion moleculesand
their interactions may be useful therapeutic targets for the
reduction of cardiovascular risk and management of CVD
[23, 24].
These CAMs are produced chieﬂy by endothelial cells,
although modest expression of ICAM-1 and VCAM-1 has
also been shown by bone marrow stromal cells and some
other cells under speciﬁc conditions [25]. Circulating levels
of CAMs increase leukocyte binding that can be accurately
quantiﬁed by FACScan analysis [1, 2]. Our results show
clearly that ICAM-1, VCAM-1 and E-selectin are detectable
on the surface of leukocytes and that treatment with DP for
12 weeks reduces expression of E-selectin and ICAM-1.
Several eﬀects of Radix Salviae Miltiorrhizae on the
cardiovascular system have been demonstrated, including
reduction of cholesterol and triglyceride levelsand enhanced
recoveryfollowing myocardial ischemia [26,27]and reduced
adhesion molecule expression [28, 29]. Radix Salviae Mil-
tiorrhizae contains multiple active chemical constituents,
of which nearly 100 have been identiﬁed. Among the
most important of these are lipophilic tanshinones such as
tanshinone IIA and hydrophilic phenolic acids, particularly
danshensu, protocatechuic aldehyde and salvianolic acid
[30].
Radix Notoginseng has been used traditionally for its
haemostatic eﬀect for internal and external bleeding [31],
is said to increase coronary blood ﬂow and reduce myocar-
dial oxygen consumption [32] and dilate coronary arteries
[26]. The active constituents of Radix Notoginseng include
arasaponin A, arasaponin B, dencichine and trilinolein [31].
Saponins have been found to lower blood lipids [33],
limit atherosclerosis by inhibiting the proliferation of aortic
smooth muscle cells [34, 35] and reduce inﬂammation
[36]. Trilinolein has antioxidant eﬀects, reduces thrombo-
genicity and suppresses cardiac arrhythmias during oxygen-
deprivationischemiainaratmodel[37].Themajorchemical
constituentsof Borneoleum Syntheticumare sesquiterpenes:
racemic borneol, isoborneol and camphor [38].
In the present study, the eﬀe c to ft h em i x t u r eo fh e r b s
containedin the DP appearsspeciﬁcally toreducecirculating
levels of the adhesion molecules ICAM-1 and E-selectin.
Taken together with the eﬀect previously demonstrated in
an animal model of reduced atherogenesis this suggests that
this product may provide a useful model for the further
investigation of the underlying mechanisms of CVD. It is
also possible that it may also contribute to the development
of novel strategies for preventing CVD and limiting the
development of existing atherosclerotic lesions. Further
research isnecessarytoidentifytheconstituentsofthisherbal
preparation, which are responsible for these actions.
It is important, however, to note the limitations of
this study, which comprised small numbers, focused on
a population of basically healthy individuals not taking
conventional medications and relied on surrogate rather
than clinical endpoints. It is possible that the eﬀects of the
herbal product are diﬀerent in other clinical settings and in
particular, in subjects with active CVD. The signiﬁcance of
changesincirculatingadhesionsmoleculesofthismagnitude
is uncertain. It is known that physical exercise can reduce
adhesion molecule expression while psychological stress can
increase it[39].Inourstudyphysicalexercisedidnotchange.
While there is no reason to believe that there were diﬀerences
in levels of psychological stress between the groups nor
changes in stress levels over the study period, we did not
measure these directly so stress should be recognized as a
potential confounding factor.
In summary, in human subjects with mild to moderately
elevated lipid levels the mixture of herbs contained in the
DP appears to have a speciﬁc eﬀect on reducing the CAMs
ICAM-1 and E-selectin. This product may contribute to the
further investigation of the mechanisms of CVD and to the
development of novel strategies for both its prevention and
management.
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